Investors have a new variable that could potentially impact investment outcomes -- the flu. Your portfolio strategy will be impacted depending on how serious the spread of swine flu is and how dramatic the resulting panic turns out to be.
Here we go again. When I was relatively new on this beat I was thrown into covering the bird flu scare. At the time, many experts said it wasn't a question of if, but when it would come to the U.S. I'm still waiting. And I hope we're all waiting forever.
The futures are down again this morning with uncertainty of the impact that the swine flu will ultimately have. So far, nearly 150 people have died in Mexico from the disease as it continues to spread around the world. Here are some of the stocks that moved most as the story has developed.
Concerns that the recent outbreak of swine flu could reach pandemic proportions dragged down the Dow and S&P Monday with investors hammering airlines, hotels and more.
Stocks bounced back from a swine flu-induced drop Monday as traders scooped up shares of drug makers and pharmacies.
The threat of a widespread swine flu outbreak weighed on the markets Monday, and for good reason: Even if the virus is contained, it's still likely to put a crimp on spending for a wide array of goods.
Concerns that the swine flu could reach pandemic proportions sent money moving. Who wins and who loses?
Swine Flu: global pandemic or paranoia? President Obama said the health emergency declaration was merely a prudent measure. But many pharmaceutical stocks were sharply higher Monday in reaction to flu outbreaks — and the gains seemed to ripple through the sector.
As author of World Event Trading, I did an entire section on infectious diseases from the 1918 Spanish Flu to Bird Flu. The recent outbreak of Swine Flu is generating headlines and concerns globally......Critical point: fear of the disease is the biggest driver of behavior and societal changes due to the outbreak.
Financials continue to lead the weakness today on the heels of Bank of America’s earnings report. In late-morning trading, B of A and Citigroup are now down 15 percent each, while many other regional banks are 11 to 15 percent lower.
In this Web Extra, Pete Najarian talks Pharma takeovers. What's on his radar?
An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.
Breakthrough diabetes treatments may be on the horizon. What companies stand to win?
A number of takeover rumors have been making the rounds, an encouraging sign that capitalistic optimism is returning to the markets.
OptionMonster Jon Najarian reveals where he's spotted some unusually bullish action.
The Pit Boss is seeing explosive options action in a drug stock. Find out which one!
Both Pete and Jon Najarian are seeing some unusual options action. What do they make of it?
Plus, Cramer discusses credit-card and drug stocks, as well as the housing bottom.
The OptionMonster is seeing unusual action in two stocks. What does he make of it?
My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.